The document is a financial analysis report by Deutsche Bank on AstraZeneca, highlighting a likely turning point for margin and EPS momentum in 2018. It discusses AstraZeneca's best-in-class pipeline, substantial margin leverage, and multiple catalysts from the pipeline. The report includes a price scenario table and projected financials from 2015 to 2022.
doj/DataSet10/EFTA01385515.pdf
{"title":"Deutsche Bank Research European Equity Focus","key_people":["Richard Parkes"],"document_date":"January 2018","document_type":"tabular","document_subtype":"financial analysis","key_organizations":["Deutsche Bank","AstraZeneca"],"reference_numbers":["DB-SDNY-0086801","SDNY_GM_00232985","EFTA01385515"]}